HEADER TRANSFERASE 07-DEC-21 7QG1 TITLE IRAK4 IN COMPLEX WITH INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: IRAK-4,RENAL CARCINOMA ANTIGEN NY-REN-64; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: IRAK4; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS KINASE INHIBITOR INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 KEYWDS 2 INTERLEUKIN-1 SIGNALING, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR Y.XUE,A.AAGAARD,G.R.ROBB,S.L.DEGORCE REVDAT 2 31-JAN-24 7QG1 1 REMARK REVDAT 1 04-MAY-22 7QG1 0 JRNL AUTH I.A.CUMMING,S.L.DEGORCE,A.AAGAARD,E.L.BRAYBROOKE,N.L.DAVIES, JRNL AUTH 2 C.R.DIENE,A.J.EATHERTON,H.R.FELSTEAD,S.D.GROOMBRIDGE, JRNL AUTH 3 E.M.LENZ,Y.LI,Y.NAI,S.PEARSON,G.R.ROBB,J.S.SCOTT, JRNL AUTH 4 O.R.STEWARD,C.WU,Y.XUE,L.ZHANG,Y.ZHANG JRNL TITL IDENTIFICATION AND OPTIMISATION OF A PYRIMIDOPYRIDONE SERIES JRNL TITL 2 OF IRAK4 INHIBITORS. JRNL REF BIOORG.MED.CHEM. V. 63 16729 2022 JRNL REFN ESSN 1464-3391 JRNL PMID 35439688 JRNL DOI 10.1016/J.BMC.2022.116729 REMARK 2 REMARK 2 RESOLUTION. 2.07 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 86.75 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 3 NUMBER OF REFLECTIONS : 41869 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.249 REMARK 3 R VALUE (WORKING SET) : 0.247 REMARK 3 FREE R VALUE : 0.285 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.060 REMARK 3 FREE R VALUE TEST SET COUNT : 2118 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.200 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.12 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.64 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 3040 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2560 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2888 REMARK 3 BIN R VALUE (WORKING SET) : 0.2560 REMARK 3 BIN FREE R VALUE : 0.2690 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 152 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4342 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 76 REMARK 3 SOLVENT ATOMS : 239 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 48.53 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 68.73 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -12.33510 REMARK 3 B22 (A**2) : -5.67910 REMARK 3 B33 (A**2) : 18.01420 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.360 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.233 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.197 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.228 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.196 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.909 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.898 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4498 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 6069 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1591 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 129 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 639 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4498 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 575 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 5312 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.16 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.93 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 20.30 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7QG1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 07-DEC-21. REMARK 100 THE DEPOSITION ID IS D_1292119523. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-FEB-15 REMARK 200 TEMPERATURE (KELVIN) : 100.000 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41936 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.070 REMARK 200 RESOLUTION RANGE LOW (A) : 86.750 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 7.800 REMARK 200 R MERGE (I) : 0.05700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.07 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.18 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.4 REMARK 200 DATA REDUNDANCY IN SHELL : 6.50 REMARK 200 R MERGE FOR SHELL (I) : 1.26600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 6RFJ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.39 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.34 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: AMMONIUM SULFATE 0.1 M HEPES PH 6.8 REMARK 280 -7.4, EVAPORATION, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 43.86950 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 54.71250 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 71.16750 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 43.86950 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 54.71250 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 71.16750 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 43.86950 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 54.71250 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 71.16750 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 43.86950 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 54.71250 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 71.16750 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 139 REMARK 465 HIS A 140 REMARK 465 HIS A 141 REMARK 465 HIS A 142 REMARK 465 HIS A 143 REMARK 465 HIS A 144 REMARK 465 HIS A 145 REMARK 465 HIS A 146 REMARK 465 GLU A 147 REMARK 465 ASN A 148 REMARK 465 LEU A 149 REMARK 465 TYR A 150 REMARK 465 PHE A 151 REMARK 465 GLN A 152 REMARK 465 GLY A 153 REMARK 465 GLU A 154 REMARK 465 ASN A 155 REMARK 465 LYS A 156 REMARK 465 SER A 157 REMARK 465 LEU A 158 REMARK 465 GLU A 159 REMARK 465 VAL A 160 REMARK 465 SER A 161 REMARK 465 ASP A 162 REMARK 465 THR A 163 REMARK 465 ARG A 164 REMARK 465 SER A 186 REMARK 465 VAL A 187 REMARK 465 GLY A 188 REMARK 465 ALA A 216 REMARK 465 ALA A 217 REMARK 465 MET A 218 REMARK 465 VAL A 219 REMARK 465 ASP A 220 REMARK 465 ILE A 221 REMARK 465 THR A 222 REMARK 465 THR A 223 REMARK 465 GLU A 224 REMARK 465 GLU A 225 REMARK 465 LEU A 226 REMARK 465 LYS A 227 REMARK 465 SER A 253 REMARK 465 ASP A 254 REMARK 465 GLY A 255 REMARK 465 ASP A 256 REMARK 465 ASP A 257 REMARK 465 LEU A 258 REMARK 465 SER A 336 REMARK 465 GLU A 337 REMARK 465 LYS A 338 REMARK 465 PHE A 339 REMARK 465 ALA A 340 REMARK 465 GLN A 341 REMARK 465 THR A 342 REMARK 465 ALA A 459 REMARK 465 SER A 460 REMARK 465 MET B 139 REMARK 465 HIS B 140 REMARK 465 HIS B 141 REMARK 465 HIS B 142 REMARK 465 HIS B 143 REMARK 465 HIS B 144 REMARK 465 HIS B 145 REMARK 465 HIS B 146 REMARK 465 GLU B 147 REMARK 465 ASN B 148 REMARK 465 LEU B 149 REMARK 465 TYR B 150 REMARK 465 PHE B 151 REMARK 465 GLN B 152 REMARK 465 GLY B 153 REMARK 465 GLU B 154 REMARK 465 ASN B 155 REMARK 465 LYS B 156 REMARK 465 SER B 157 REMARK 465 LEU B 158 REMARK 465 GLU B 159 REMARK 465 VAL B 160 REMARK 465 SER B 161 REMARK 465 ASP B 162 REMARK 465 THR B 163 REMARK 465 ALA B 217 REMARK 465 MET B 218 REMARK 465 VAL B 219 REMARK 465 ASP B 220 REMARK 465 ILE B 221 REMARK 465 THR B 222 REMARK 465 GLU B 337 REMARK 465 LYS B 338 REMARK 465 PHE B 339 REMARK 465 ALA B 340 REMARK 465 GLN B 341 REMARK 465 THR B 342 REMARK 465 VAL B 343 REMARK 465 ALA B 459 REMARK 465 SER B 460 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 181 102.88 -59.09 REMARK 500 ASN A 206 -97.04 92.74 REMARK 500 THR A 208 94.36 -51.01 REMARK 500 ARG A 310 -2.97 75.05 REMARK 500 ASP A 311 49.50 -149.05 REMARK 500 ASP A 320 -165.72 -78.66 REMARK 500 ASP A 329 76.86 55.10 REMARK 500 ASP B 181 103.98 -46.08 REMARK 500 ASN B 207 -8.56 73.39 REMARK 500 SER B 253 -135.03 -127.59 REMARK 500 ASP B 254 -77.79 72.09 REMARK 500 ARG B 310 -2.57 75.97 REMARK 500 ASP B 311 48.24 -150.28 REMARK 500 ASP B 320 -166.87 -78.65 REMARK 500 ASP B 329 77.10 66.68 REMARK 500 REMARK 500 REMARK: NULL DBREF 7QG1 A 154 460 UNP Q9NWZ3 IRAK4_HUMAN 154 460 DBREF 7QG1 B 154 460 UNP Q9NWZ3 IRAK4_HUMAN 154 460 SEQADV 7QG1 MET A 139 UNP Q9NWZ3 INITIATING METHIONINE SEQADV 7QG1 HIS A 140 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS A 141 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS A 142 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS A 143 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS A 144 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS A 145 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS A 146 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 GLU A 147 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 ASN A 148 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 LEU A 149 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 TYR A 150 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 PHE A 151 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 GLN A 152 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 GLY A 153 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 MET B 139 UNP Q9NWZ3 INITIATING METHIONINE SEQADV 7QG1 HIS B 140 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS B 141 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS B 142 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS B 143 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS B 144 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS B 145 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 HIS B 146 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 GLU B 147 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 ASN B 148 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 LEU B 149 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 TYR B 150 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 PHE B 151 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 GLN B 152 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG1 GLY B 153 UNP Q9NWZ3 EXPRESSION TAG SEQRES 1 A 322 MET HIS HIS HIS HIS HIS HIS HIS GLU ASN LEU TYR PHE SEQRES 2 A 322 GLN GLY GLU ASN LYS SER LEU GLU VAL SER ASP THR ARG SEQRES 3 A 322 PHE HIS SER PHE SER PHE TYR GLU LEU LYS ASN VAL THR SEQRES 4 A 322 ASN ASN PHE ASP GLU ARG PRO ILE SER VAL GLY GLY ASN SEQRES 5 A 322 LYS MET GLY GLU GLY GLY PHE GLY VAL VAL TYR LYS GLY SEQRES 6 A 322 TYR VAL ASN ASN THR THR VAL ALA VAL LYS LYS LEU ALA SEQRES 7 A 322 ALA MET VAL ASP ILE THR THR GLU GLU LEU LYS GLN GLN SEQRES 8 A 322 PHE ASP GLN GLU ILE LYS VAL MET ALA LYS CYS GLN HIS SEQRES 9 A 322 GLU ASN LEU VAL GLU LEU LEU GLY PHE SER SER ASP GLY SEQRES 10 A 322 ASP ASP LEU CYS LEU VAL TYR VAL TYR MET PRO ASN GLY SEQRES 11 A 322 SER LEU LEU ASP ARG LEU SER CYS LEU ASP GLY THR PRO SEQRES 12 A 322 PRO LEU SER TRP HIS MET ARG CYS LYS ILE ALA GLN GLY SEQRES 13 A 322 ALA ALA ASN GLY ILE ASN PHE LEU HIS GLU ASN HIS HIS SEQRES 14 A 322 ILE HIS ARG ASP ILE LYS SER ALA ASN ILE LEU LEU ASP SEQRES 15 A 322 GLU ALA PHE THR ALA LYS ILE SER ASP PHE GLY LEU ALA SEQRES 16 A 322 ARG ALA SER GLU LYS PHE ALA GLN THR VAL MET TPO SEP SEQRES 17 A 322 ARG ILE VAL GLY THR THR ALA TYR MET ALA PRO GLU ALA SEQRES 18 A 322 LEU ARG GLY GLU ILE THR PRO LYS SER ASP ILE TYR SER SEQRES 19 A 322 PHE GLY VAL VAL LEU LEU GLU ILE ILE THR GLY LEU PRO SEQRES 20 A 322 ALA VAL ASP GLU HIS ARG GLU PRO GLN LEU LEU LEU ASP SEQRES 21 A 322 ILE LYS GLU GLU ILE GLU ASP GLU GLU LYS THR ILE GLU SEQRES 22 A 322 ASP TYR ILE ASP LYS LYS MET ASN ASP ALA ASP SER THR SEQRES 23 A 322 SER VAL GLU ALA MET TYR SER VAL ALA SER GLN CYS LEU SEQRES 24 A 322 HIS GLU LYS LYS ASN LYS ARG PRO ASP ILE LYS LYS VAL SEQRES 25 A 322 GLN GLN LEU LEU GLN GLU MET THR ALA SER SEQRES 1 B 322 MET HIS HIS HIS HIS HIS HIS HIS GLU ASN LEU TYR PHE SEQRES 2 B 322 GLN GLY GLU ASN LYS SER LEU GLU VAL SER ASP THR ARG SEQRES 3 B 322 PHE HIS SER PHE SER PHE TYR GLU LEU LYS ASN VAL THR SEQRES 4 B 322 ASN ASN PHE ASP GLU ARG PRO ILE SER VAL GLY GLY ASN SEQRES 5 B 322 LYS MET GLY GLU GLY GLY PHE GLY VAL VAL TYR LYS GLY SEQRES 6 B 322 TYR VAL ASN ASN THR THR VAL ALA VAL LYS LYS LEU ALA SEQRES 7 B 322 ALA MET VAL ASP ILE THR THR GLU GLU LEU LYS GLN GLN SEQRES 8 B 322 PHE ASP GLN GLU ILE LYS VAL MET ALA LYS CYS GLN HIS SEQRES 9 B 322 GLU ASN LEU VAL GLU LEU LEU GLY PHE SER SER ASP GLY SEQRES 10 B 322 ASP ASP LEU CYS LEU VAL TYR VAL TYR MET PRO ASN GLY SEQRES 11 B 322 SER LEU LEU ASP ARG LEU SER CYS LEU ASP GLY THR PRO SEQRES 12 B 322 PRO LEU SER TRP HIS MET ARG CYS LYS ILE ALA GLN GLY SEQRES 13 B 322 ALA ALA ASN GLY ILE ASN PHE LEU HIS GLU ASN HIS HIS SEQRES 14 B 322 ILE HIS ARG ASP ILE LYS SER ALA ASN ILE LEU LEU ASP SEQRES 15 B 322 GLU ALA PHE THR ALA LYS ILE SER ASP PHE GLY LEU ALA SEQRES 16 B 322 ARG ALA SER GLU LYS PHE ALA GLN THR VAL MET TPO SEP SEQRES 17 B 322 ARG ILE VAL GLY THR THR ALA TYR MET ALA PRO GLU ALA SEQRES 18 B 322 LEU ARG GLY GLU ILE THR PRO LYS SER ASP ILE TYR SER SEQRES 19 B 322 PHE GLY VAL VAL LEU LEU GLU ILE ILE THR GLY LEU PRO SEQRES 20 B 322 ALA VAL ASP GLU HIS ARG GLU PRO GLN LEU LEU LEU ASP SEQRES 21 B 322 ILE LYS GLU GLU ILE GLU ASP GLU GLU LYS THR ILE GLU SEQRES 22 B 322 ASP TYR ILE ASP LYS LYS MET ASN ASP ALA ASP SER THR SEQRES 23 B 322 SER VAL GLU ALA MET TYR SER VAL ALA SER GLN CYS LEU SEQRES 24 B 322 HIS GLU LYS LYS ASN LYS ARG PRO ASP ILE LYS LYS VAL SEQRES 25 B 322 GLN GLN LEU LEU GLN GLU MET THR ALA SER MODRES 7QG1 TPO A 345 THR MODIFIED RESIDUE MODRES 7QG1 SEP A 346 SER MODIFIED RESIDUE MODRES 7QG1 TPO B 345 THR MODIFIED RESIDUE MODRES 7QG1 SEP B 346 SER MODIFIED RESIDUE HET TPO A 345 11 HET SEP A 346 10 HET TPO B 345 11 HET SEP B 346 10 HET B8I A 501 38 HET B8I B 501 38 HETNAM TPO PHOSPHOTHREONINE HETNAM SEP PHOSPHOSERINE HETNAM B8I METHYL 4-[4-[[6-(CYANOMETHYL)-2-[(1-METHYLPYRAZOL-4- HETNAM 2 B8I YL)AMINO]-5-OXIDANYLIDENE-PYRIDO[4,3-D]PYRIMIDIN-4- HETNAM 3 B8I YL]AMINO]CYCLOHEXYL]PIPERAZINE-1-CARBOXYLATE HETSYN TPO PHOSPHONOTHREONINE HETSYN SEP PHOSPHONOSERINE FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 1 SEP 2(C3 H8 N O6 P) FORMUL 3 B8I 2(C25 H32 N10 O3) FORMUL 5 HOH *239(H2 O) HELIX 1 AA1 SER A 169 THR A 177 1 9 HELIX 2 AA2 PHE A 230 CYS A 240 1 11 HELIX 3 AA3 SER A 269 SER A 275 1 7 HELIX 4 AA4 CYS A 276 THR A 280 5 5 HELIX 5 AA5 SER A 284 ASN A 305 1 22 HELIX 6 AA6 LYS A 313 ALA A 315 5 3 HELIX 7 AA7 THR A 351 MET A 355 5 5 HELIX 8 AA8 ALA A 356 ARG A 361 1 6 HELIX 9 AA9 THR A 365 GLY A 383 1 19 HELIX 10 AB1 LEU A 395 LEU A 397 5 3 HELIX 11 AB2 ASP A 398 ASP A 405 1 8 HELIX 12 AB3 THR A 409 ILE A 414 1 6 HELIX 13 AB4 ASP A 422 LEU A 437 1 16 HELIX 14 AB5 LYS A 440 ARG A 444 5 5 HELIX 15 AB6 ASP A 446 THR A 458 1 13 HELIX 16 AB7 SER B 169 THR B 177 1 9 HELIX 17 AB8 PRO B 184 GLY B 188 5 5 HELIX 18 AB9 GLU B 224 CYS B 240 1 17 HELIX 19 AC1 SER B 269 SER B 275 1 7 HELIX 20 AC2 CYS B 276 THR B 280 5 5 HELIX 21 AC3 SER B 284 ASN B 305 1 22 HELIX 22 AC4 LYS B 313 ALA B 315 5 3 HELIX 23 AC5 THR B 351 MET B 355 5 5 HELIX 24 AC6 ALA B 356 ARG B 361 1 6 HELIX 25 AC7 THR B 365 GLY B 383 1 19 HELIX 26 AC8 LEU B 395 LEU B 397 5 3 HELIX 27 AC9 ASP B 398 ASP B 405 1 8 HELIX 28 AD1 THR B 409 ILE B 414 1 6 HELIX 29 AD2 ASP B 422 LEU B 437 1 16 HELIX 30 AD3 LYS B 440 ARG B 444 5 5 HELIX 31 AD4 ASP B 446 THR B 458 1 13 SHEET 1 AA1 6 HIS A 166 SER A 167 0 SHEET 2 AA1 6 LEU A 248 PHE A 251 1 O LEU A 249 N HIS A 166 SHEET 3 AA1 6 LEU A 260 VAL A 263 -1 O VAL A 261 N GLY A 250 SHEET 4 AA1 6 THR A 208 LYS A 214 -1 N LYS A 213 O LEU A 260 SHEET 5 AA1 6 VAL A 199 VAL A 205 -1 N GLY A 203 O VAL A 210 SHEET 6 AA1 6 LYS A 191 GLU A 194 -1 N MET A 192 O VAL A 200 SHEET 1 AA2 2 ILE A 317 LEU A 319 0 SHEET 2 AA2 2 ALA A 325 ILE A 327 -1 O LYS A 326 N LEU A 318 SHEET 1 AA3 6 HIS B 166 SER B 167 0 SHEET 2 AA3 6 LEU B 248 SER B 252 1 O LEU B 249 N HIS B 166 SHEET 3 AA3 6 CYS B 259 VAL B 263 -1 O VAL B 261 N GLY B 250 SHEET 4 AA3 6 THR B 208 LEU B 215 -1 N LYS B 213 O LEU B 260 SHEET 5 AA3 6 GLY B 198 VAL B 205 -1 N TYR B 201 O VAL B 212 SHEET 6 AA3 6 LYS B 191 GLU B 194 -1 N GLY B 193 O VAL B 200 SHEET 1 AA4 2 HIS B 307 ILE B 308 0 SHEET 2 AA4 2 ARG B 334 ALA B 335 -1 O ARG B 334 N ILE B 308 SHEET 1 AA5 2 ILE B 317 LEU B 319 0 SHEET 2 AA5 2 ALA B 325 ILE B 327 -1 O LYS B 326 N LEU B 318 LINK C MET A 344 N TPO A 345 1555 1555 1.35 LINK C TPO A 345 N SEP A 346 1555 1555 1.35 LINK C SEP A 346 N ARG A 347 1555 1555 1.36 LINK C MET B 344 N TPO B 345 1555 1555 1.35 LINK C TPO B 345 N SEP B 346 1555 1555 1.35 LINK C SEP B 346 N ARG B 347 1555 1555 1.36 CISPEP 1 GLU A 392 PRO A 393 0 1.09 CISPEP 2 GLU B 392 PRO B 393 0 1.45 CRYST1 87.739 109.425 142.335 90.00 90.00 90.00 I 2 2 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011397 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009139 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007026 0.00000